TriNetX Expands Global Multiomic Capabilities Through Acquisition of Zetta Genomics Key Assets

Strengthening Federated Genomic Research

TriNetX announced today that it has acquired the key assets of Zetta Genomics, a healthcare technology firm based in Cambridge, UK. The transaction includes the award-winning XetaBase technology, a platform designed for population-scale genomic analysis. This move allows TriNetX to integrate multiomic data management directly into its global federated health data network, supporting a more localized approach to scaling research infrastructure.

Bridging Phenotypic and Multiomic Data

The integration of XetaBase will bridge the gap between phenotypic data and complex genomic information for researchers. By utilizing a federated architecture, the platform enables secure data querying without requiring healthcare providers to move sensitive patient records into centralized silos. This system supports real-time discovery and the continuous re-interpretation of genetic variants as new scientific insights emerge in the field of precision medicine.

This acquisition is the culmination of a deep technical partnership established between the two companies in 2024. Over the past two years, TriNetX and Zetta have successfully demonstrated the feasibility of secure, high-integrity querying across diverse datasets. This proven track record provided the foundation for the full asset integration announced this week, ensuring that the technology is already validated for large-scale use.

Jeff Margolis, the Executive Chairman of TriNetX, stated that welcoming the XetaBase platform marks an important milestone for the organization. He noted that the acquisition reflects a commitment to advancing research through a practical approach to data infrastructure. The company intends to continue supporting all existing Zetta Genomics customers, including leading healthcare provider organizations and life sciences companies, during this transition.

A Legacy of Innovation

Zetta Genomics originated as a spin-out from the University of Cambridge and Genomics England to tackle the data complexities of the 100,000 Genomes Project. Under the leadership of Ignacio Medina Castello, the firm developed specialized tools to replace slow, legacy genomic analysis methods. Joining TriNetX allows this specialized technology to reach a broader global community of research partners and healthcare providers immediately. TriNetX currently connects more than 11,000 healthcare provider sites across 20 countries, providing a massive scale for real-world evidence and patient care. By adding multiomic capabilities, the network enhances its ability to support precision medicine and clinical trial design. This development helps life science companies perform large-scale genomic research more cost-effectively while maintaining strict data privacy standards across the globe.